2:46 PM
 | 
Jun 25, 2019
 |  BC Extra  |  Company News

Gilead to add lipid kinase inhibitors to pipeline via Carna deal

Gilead has partnered with Carna to develop small molecule inhibitors of lipid kinases in the bellwether’s second deal to bolster its cancer portfolio since CEO Daniel O’Day arrived.

Gilead Sciences Inc. (NASDAQ:GILD) will pay...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >